EUR-Lex & EU Commission AI-Powered Semantic Search Engine
Modern Legal
  • Query in any language with multilingual search
  • Access EUR-Lex and EU Commission case law
  • See relevant paragraphs highlighted instantly
Start free trial

Similar Documents

Explore similar documents to your case.

We Found Similar Cases for You

Sign up for free to view them and see the most relevant paragraphs highlighted.

Case C-207/19 P: Judgment of the Court (First Chamber) of 27 June 2024 – Biogaran SAS v European Commission (Appeal – Competition – Pharmaceutical products – Market for perindopril – Article 101 TFEU – Strategy to delay the market entry of generic versions of perindopril – Patent dispute settlement agreement – Licence and supply agreement)

ECLI:EU:UNKNOWN:62019CA0207

62019CA0207

June 27, 2024
With Google you find a lot.
With us you find everything. Try it now!

I imagine what I want to write in my case, I write it in the search engine and I get exactly what I wanted. Thank you!

Valentina R., lawyer

Official Journal of the European Union

C series

C/2024/4829

12.8.2024

(Case C-207/19 P)

(Appeal - Competition - Pharmaceutical products - Market for perindopril - Article 101 TFEU - Strategy to delay the market entry of generic versions of perindopril - Patent dispute settlement agreement - Licence and supply agreement)

(C/2024/4829)

Language of the case: French

Parties

Appellant: Biogaran SAS (represented by: O. de Juvigny, J. Jourdan, T. Reymond, A. Robert, avocats, J. Killick, advocaat, and M.I.F. Utges Manley, Solicitor)

Other party to the proceedings: European Commission (represented initially by F. Castilla Contreras, B. Mongin, and C. Vollrath, acting as Agents, and subsequently by F. Castilla Contreras and C. Vollrath, acting as Agents)

Intervener in support of the other party: United Kingdom of Great Britain and Northern Ireland (represented initially by D. Guðmundsdóttir, acting as Agent, and subsequently by S. Fuller, acting as Agent)

Operative part of the judgment

The Court:

1.Dismisses the appeal;

2.Orders Biogaran SAS to bear its own costs and to pay those incurred by the European Commission;

3.Orders the United Kingdom of Great Britain and Northern Ireland to bear its own costs.

(1)

OJ C 139, 15.4.2019.

ELI: http://data.europa.eu/eli/C/2024/4829/oj

ISSN 1977-091X (electronic edition)

EurLex Case Law

AI-Powered Case Law Search

Query in any language with multilingual search
Access EUR-Lex and EU Commission case law
See relevant paragraphs highlighted instantly

Get Instant Answers to Your Legal Questions

Cancel your subscription anytime, no questions asked.Start 14-Day Free Trial

At Modern Legal, we’re building the world’s best search engine for legal professionals. Access EU and global case law with AI-powered precision, saving you time and delivering relevant insights instantly.

Contact Us

Tivolska cesta 48, 1000 Ljubljana, Slovenia